-
Nigeria signals more strikes likely in 'joint' US operations
-
Malaysia's former PM Najib convicted in 1MDB graft trial
-
Elusive wild cat feared extinct rediscovered in Thailand
-
Japan govt approves record budget, including for defence
-
Seoul to ease access to North Korean newspaper
-
History-maker Tongue wants more of the same from England attack
-
Australia lead England by 46 after 20 wickets fall on crazy day at MCG
-
Asia markets edge up as precious metals surge
-
Twenty wickets fall on day one as Australia gain edge in 4th Ashes Test
-
'No winner': Kosovo snap poll unlikely to end damaging deadlock
-
Culture being strangled by Kosovo's political crisis
-
Main contenders in Kosovo's snap election
-
Australia all out for 152 as England take charge of 4th Ashes Test
-
Boys recount 'torment' at hands of armed rebels in DR Congo
-
Inside Chernobyl, Ukraine scrambles to repair radiation shield
-
Bondi victims honoured as Sydney-Hobart race sets sail
-
North Korea's Kim orders factories to make more missiles in 2026
-
Palladino's Atalanta on the up as Serie A leaders Inter visit
-
Hooked on the claw: how crane games conquered Japan's arcades
-
Shanghai's elderly waltz back to the past at lunchtime dance halls
-
Japan govt approves record 122 trillion yen budget
-
US launches Christmas Day strikes on IS targets in Nigeria
-
Australia reeling on 72-4 at lunch as England strike in 4th Ashes Test
-
Too hot to handle? Searing heat looming over 2026 World Cup
-
Packers clinch NFL playoff spot as Lions lose to Vikings
-
Guinea's presidential candidates hold final rallies before Sunday's vote
-
A Christmas Message to the DEA's Diversion Anti Marijuana Cabal
-
QAT Community Sets QuantumTrade 5.0 for Public Beta Testing in March 2026
-
BondwithPet Expands B2B Offering with Custom Pet Memorial Product
-
Best Crypto IRA Companies (Rankings Released)
-
Eon Prime Intelligent Alliance Office Unveils New Brand Identity and Completes Website Upgrade
-
Villa face Chelsea test as Premier League title race heats up
-
Spurs extend domination of NBA-best Thunder
-
Malaysia's Najib to face verdict in mega 1MDB graft trial
-
King Charles calls for 'reconciliation' in Christmas speech
-
Brazil's jailed ex-president Bolsonaro undergoes 'successful' surgery
-
UK tech campaigner sues Trump administration over US sanctions
-
New Anglican leader says immigration debate dividing UK
-
Russia says made 'proposal' to France over jailed researcher
-
Bangladesh PM hopeful Rahman returns from exile ahead of polls
-
Police suspect suicide bomber behind Nigeria's deadly mosque blast
-
AFCON organisers allowing fans in for free to fill empty stands: source
-
Mali coach Saintfiet hits out at European clubs, FIFA over AFCON changes
-
Last Christians gather in ruins of Turkey's quake-hit Antakya
-
Pope Leo condemns 'open wounds' of war in first Christmas homily
-
Mogadishu votes in first local elections in decades under tight security
-
'Starting anew': Indonesians in disaster-struck Sumatra hold Christmas mass
-
Cambodian PM's wife attends funerals of soldiers killed in Thai border clashes
-
Prime minister hopeful Tarique Rahman arrives in Bangladesh: party
-
Pacific archipelago Palau agrees to take migrants from US
Biden calls for lower prices of Ozempic, similar drugs
US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."
In an article written with Senator Bernie Sanders, Biden said US patients pay several times more than in Canada, Germany and Denmark for Nordisk's diabetes drugs Ozempic and Wegovy, which can also be used for weight loss.
One-month supply of Ozempic in the United States last year was $936, compared to $169 in Canada and $103 in Germany, according to one study.
Eli Lilly was also charging "unconscionably high prices" for Mounjaro, a drug similar to Ozempic.
"Why should people in Burlington, Vermont, pay so much more than people in Copenhagen or Berlin for the same drug?" wrote Biden and Sanders, who chairs the Senate healthcare committee.
Such "price gouging" makes the drugs unaffordable to millions of Americans, they said.
"If the prices of these drugs are not substantially reduced, they have the potential to bankrupt the American health care system," Biden and Sanders wrote. "We will not allow that to happen."
Nordisk and Lilly did not immediately respond to an AFP request for comment.
High prices for prescription drugs have been a long-standing problem for American patients, and Democrat Biden has focused on lowering healthcare costs as part of his reelection campaign in November.
The piece in USA Today comes days after Biden's weak performance during a televised presidential debate with Republican Donald Trump sparked sharp concern among Democrats.
M.Fischer--AMWN